MedWatch

Zealand Pharma moves into US biotech giant's territory

Zealand Pharma expands its rare disease pre-clinical pipeline to a field dominated by US-based drug group Alexion. Moreover, the Danish biotech company adds a new intestinal disease candidate to its pre-clinical pipeline.

Foto: Zealand Pharma PR

Danish biotech company Zealand Pharma has established a business based on research and development of therapeutic peptides.

Previously, Zealand was mainly associated with metabolic diseases like diabetes, but during the past years the company has moved into other fields, too. Gastrointestinal diseases have become another focus point because of the company's main candidate glepaglutide against short bowel syndrome.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier